

**Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

Claims 1-5 (Cancelled).

6(Currently amended). A pharmaceutical composition, comprising ~~[[the]]~~ a polypeptide of claim 1 as an active ingredient and a pharmaceutically-acceptable carrier, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of:

(a) SEQ ID NO:6, where amino acid residue 73, as represented by Xaa, is Ile or Thr;

(b) a contiguous fragment of SEQ ID NO:6, which fragment induces interferon- $\gamma$  production in immunocompetent human cells and has a molecular weight of about 18,500  $\pm$  3,000 daltons on sodium dodecyl sulfate polyacrylamide gel electrophoresis; and

(c) a variant of (a) or (b) differing therefrom by replacement of one amino acid residue, which variant induces interferon- $\gamma$  production in immunocompetent human cells.

7(Original). The pharmaceutical composition of claim 6, further comprising interleukin 2.

8(Original). The pharmaceutical composition of claim 6, further comprising interleukin 12.

9(Original). The pharmaceutical composition of claim 6, further comprising interleukin 3.

Claims 10-18 (Cancelled)

19(Currently amended). A pharmaceutical composition, comprising (i) an interferon- $\gamma$  inducing polypeptide having the amino acid sequence of SEQ ID NO:6[[,]] (where amino acid residue 73, as represented by Xaa, is Ile or Thr)[[,]] or a fragment thereof, [[and]] said polypeptide having the following physicochemical properties:

(1) molecular weight

18,500 . 3,000 daltons on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE);

(2) isoelectric point (pI)

4.9 . 1.0 on chromatofocusing;

(3) biological activity

inducing interferon- $\gamma$  production by human immunocompetent cells;

(4) acute toxicity

having an LD<sub>50</sub> of at least about one mg/kg when tested in mice; and

(5) assay

Appln. No. 09/716,356  
Amd. dated June 9, 2006  
Reply to Office Action of March 28, 2006

being detected with a monoclonal antibody which  
binds to the interferon- $\gamma$  inducing polypeptide  
having an amino acid sequence of SEQ ID NO:6;  
(ii) a pharmaceutically acceptable carrier; and  
(iii) may optionally comprise one or more compounds selected from  
the group consisting of an adjuvant, excipient, diluent,  
stabilizer, and a second biologically active compound.

Claims 20-94 (Cancelled).